Tracers / [131I]I-ERIC1
[131I]I-ERIC1
Also written as [I-131]I-ERIC1
- Radionuclide
- I-131 t½ 11549 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 1
What it is
- Compound class
- Anti-NCAM monoclonal antibody (radioimmunoconjugate)
- Target / mechanism
- Neural cell adhesion molecule (NCAM) PMID 39409066
- Clinical application
- Neuroblastoma PMID 39409066
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | 50-60% | >95% | ERIC1 antibody | 39409066 2024 Int J Mol Sci The antibody ERIC1 (0.1 mg/mL) was radiolabeled with varying activities of 131I using a variant of the chloramine-T method. — The labeling of ERIC1 with I-131 achieved a yield of approximately 50–60% |
Need this precursor?We can point you to suppliers for [131I]I-ERIC1, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 39409066. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 39409066: 'The antibody ERIC1 (0.1 mg/mL) was radiolabeled with varying activities of 131I'. Stage set/updated at stage 23 from PMID 39409066: 'Tumoricidal Activity and Side Effects of Radiolabeled Anti-NCAM [131I]-Iodine-ERIC1 in Neuroblastoma-Bearing Mice.'.